GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nutex Health NUTX · USD

Health Care · US listing · 🇺🇸 United States

Compare

194.16

+7.53%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$875.3m

FY2016FY2025

Net income

$70.8m

FY2016FY2025

Free cash flow

$245.6m

FY2016FY2025

Shareholders' equity

$329.4m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$875.3m$479.9m$247.6m$219.3m$331.5m$274.0m$97.1m$91,373$53,647—
Research and development————$285,880$557,257$768,103$545,223$25,645—
Operating income$275.6m$130.6m−$32.2m−$407.2m$170.3m$153.2m$34.7m−$1.8m−$5.7m−$448,600
Net income$70.8m$52.2m−$45.8m−$424.8m$132.6m$106.0m$20.9m−$2.8m$582,062−$7.4m
Diluted earnings per share9.8610.23-10.86-86.3833.550.164.62-0.390.16-14,864.48

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$918.5m$655.3m$398.2m$431.8m$394.7m$308.6m$179.2m$449,428$3.3m$510,835
Cash and short-term investments$185.6m$43.6m$22.0m$34.3m$36.1m$25.5m$8.0m$119,267$9,449$10,522
Total liabilities$495.1m$453.4m$319.1m$311.4m$203.1m$161.2m$128.4m$1.9m$959,780$6.4m
Debt$351.4m$340.3m$275.8m$267.2m$178.6m$150.1m$119.9m$1.4m$386,189$50,000
Shareholders' equity$329.4m$146.3m$61.5m$95.9m$114.7m$85.8m$28.3m−$1.5m$2.4m−$5.9m
Shares outstanding7m5m4m5m4m644m5m7m4m0m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$248.1m$23.2m$1.3m$50.6m$173.4m$81.3m$12.1m−$480,049−$714,623−$274,223
Capital spending−$2.5m−$2.3m−$9.5m−$14.6m−$36.9m−$61.2m−$32.3m—−$3−$3
Free cash flow$245.6m$20.8m−$8.2m$36.0m$136.5m$20.1m−$20.2m−$480,049−$714,626−$274,226
Dividends paid−$74.3m−$6.4m−$5.2m−$51.2m−$144.3m−$59.1m−$18.9m———

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$210.8m$216.5m$151.7m$267.8m$244.0m$211.8m$257.6m$78.8m
Operating income$121.7m$81.3m$30.9m$130.4m$33.7m$72.2m$114.2m$9.7m
Net income$65.8m$46.8m$11.8m$55.4m−$17.7m$14.6m$61.7m−$8.8m
Diluted earnings per share9.386.671.657.72-2.472.0412.10-1.72
Cash from operations$34.0m$75.0m$70.0m$99.0m$27.0m$50.0m—$6.0m
Capital spending−$2.0m−$1.0m−$1.0m—————
Free cash flow$32.0m$74.0m$69.0m—————
Total assets$964.6m$957.3m$918.5m$964.5m$841.0m$761.9m$655.3m$438.5m
Cash and short-term investments$205.2m$207.3m$185.6m$166.0m—$84.7m$43.6m$46.9m
Debt$49.2m$50.7m$52.5m$58.1m$20.5m$52.6m$50.2m$17.85bn
Shareholders' equity$394.3m$346.3m$329.4m$317.2m$235.3m$197.1m$146.3m$79.8m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue58.6%26.1%—
Operating income—12.5%—
Net income—-7.8%96.2%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin30.0%-1.8%12.0%—
Net margin9.1%-19.1%-4.5%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings16.73.1-2.5-3.3
Price to sales1.40.30.56.4

Share price return

Finished calendar years

2025202420232022
Return456%12%-90%-95%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 3 Jul 2024
  • 15-to-1 reverse split · 10 Apr 2024
  • 500-to-1 reverse split · 1 Nov 2019

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.